Merck’s Investigational Oral PCSK9 Inhibitor Enlicitide Decanoate Met All Primary and Key Secondary Endpoints in Adults with Hypercholesterolemia in Pivotal CORALreef Lipids Study
(NYSE:MRK) RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Enlicitide is the first oral PCSK9 inhibitor to demonstrate statistically significant and clinically meaningful reductions in LDL-C in Phase 3
Related Questions
How will the Phase 3 results for Enlicitide influence Merck’s upcoming earnings guidance and stock valuation?
What are the anticipated timelines for regulatory approval and market launch of the oral PCSK9 inhibitor, and how might that affect the share price?
How does Enlicitide’s efficacy and safety profile compare to existing injectable PCSK9 therapies and other emerging oral competitors, and what could that mean for Merck’s market share in hypercholesterolemia treatment?